Back to Watchlist

Evidence memo

Rapamycin / sirolimus

Also tracked as: Sirolimus, rapamycin

An approved drug in specific medical contexts and a central longevity research compound, but human anti-aging claims remain unsettled.

Context-dependent Approved specific use Safety watch

Evidence status

Peptide and compound claims to watch. Evidence level: Context-dependent.

Claim being evaluated

Whether mTOR modulation can produce clinically meaningful human healthspan benefits outside approved disease contexts.

Why people care

Rapamycin is one of the most discussed geroscience compounds because animal and mechanistic evidence is strong.

Signal so far

Approved-use evidence belongs to specific medical indications. Human longevity evidence is exploratory and context-dependent.

Biggest unknown

Net benefit in otherwise healthy people, immune and metabolic tradeoffs, cancer-context complexity, and validated aging endpoints.

Safety/regulatory boundary

Approved drug status does not validate off-label longevity use.

Watch next

Larger human geroscience trials, adverse-event reporting, and biomarker-to-outcome translation.

Evidence interpretation

One of the most important longevity watch items, precisely because the evidence is strong in models and still incomplete in humans.

References